Advice
in the absence of a submission from the holder of the marketing authorisation:
rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride (Voractiv®) is not recommended for use within NHS Scotland.
Indication under review: initial treatment of tuberculosis according to World Health Organisation (WHO) guidelines.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride (Voractiv)
- SMC ID:
- 876/13
- Indication:
- Initial treatment of tuberculosis according to World Health Organisation (WHO) guidelines.
- Pharmaceutical company
- Genus Pharmaceuticals
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 May 2013